Abstracts Archive - Page 1420 of 2607 - ACR Meeting Abstracts

Abstract Number: 491 • 2017 ACR/ARHP Annual Meeting
Streptococcus Species Enriched in the Oral Cavity of RA Patients: A Persistent Source of Peptidoglycan-Polysaccharide Polymers Which Drive Disseminated Synovial Inflammation
Rabia Moentadj¹, Linda Rehaume², Paraic O Cuiv³, Kate Ormerod⁴, Muralidhara Maradana³, Vanessa Anne Lakis³, Mark Morrison², Philip Hugenholtz⁴, Helen Benham⁵, Kim-Anh Lê Cao⁶ and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, ⁵The University of Queensland Faculty of Medicine, Brisbane, Australia, ⁶School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia
Background/Purpose: In Rheumatoid Arthritis (RA), genetic predisposition and environmental risk factors promote dysbiosis of oral and fecal microbiota. We hypothesized that specific microbial taxa (operational…
Abstract Number: 492 • 2017 ACR/ARHP Annual Meeting
Is Leukotoxin_A Produced By Aggregatibacter Actynomycetemcomitans Important for Initiating Autoimmune Responses Underlying Rheumatoid Arthritis?
Mikhail Volkov¹, Jacqueline Dekkers¹, Bruno G. Loos², Sergio Bizzarro², Tom W.J. Huizinga³, Helle A. Praetorius⁴, Rene E.M. Toes⁵ and Diane van der Woude¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Periodontology, Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit, Amsterdam, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁴Department of Biomedicine, Aarhus University, Aarhus, Denmark, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In a recent publication in Science Translational Medicine, Konig et al. (2016) describe a potential explanation for the link between periodontal infection and RA.…
Abstract Number: 493 • 2017 ACR/ARHP Annual Meeting
Methotrexate Is an Antibacterial Drug Metabolized By Human Gut Bacteria
Renuka R. Nayak¹, Kye Stapleton-Gray², Colleen O'Loughlin³, Michael Fischbach⁴ and Peter J. Turnbaugh⁵, ¹Department of Medicine, Division of Rheumatology, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, ²Carnegie Mellon University, Pittsburgh, PA, ³University of California, San Francisco, San Francisco, CA, ⁴Department of Bioengineering and Therapeutic Sciences,, University of California, San Francisco, San Francisco, CA, ⁵Microbiology and Immunology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology causing inflammation and irreversible damage in joints and other organs. Methotrexate (MTX) is first-line…
Abstract Number: 494 • 2017 ACR/ARHP Annual Meeting
The Oral Microbiome Is Altered in Patients with Rheumatoid Arthritis
Sheila Arvikar¹, Hatice Hasturk², Klemen Strle³, Daniel Nguyen⁴, Marcy B. Bolster⁵, Deborah Collier⁶, Alpdogan Kantarci² and Allen Steere¹, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ²Department of Applied Oral Health Sciences, Forsyth, Cambridge, MA, ³Department of Immunology and Inflammatory Diseases, Massachusetts General Hospital, BOSTON, MA, ⁴Forsyth, Cambridge, MA, ⁵Rheumatology, Allergy and Immunology, Endocrine Associates, Massachusetts General Hospital, Boston, MA, ⁶Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The mouth is the second most abundantly colonized mucosal surface in the human body. Periodontitis, a polymicrobial infectious and inflammatory disease of tooth-supporting structures,…
Abstract Number: 495 • 2017 ACR/ARHP Annual Meeting
Efficacy of Tofacitinib in Patients with Moderate to Severe Rheumatoid Arthritis By Baseline C-Reactive Protein Levels and Erythrocyte Sedimentation Rates
Sergio Schwartzman¹, Ronald F van Vollenhoven², Alan K Matsumoto³, Dana Orange⁴, Shweta Shah⁵, Ryan DeMasi⁵, Haiyun Fan⁵, Palle Dahl⁶, Ann Wouters⁷ and Edward C. Keystone⁸, ¹Hospital for Special Surgery, New York, NY, ²Karolinska Institute, Stockholm, Sweden, ³Arthritis & Rheumatism Associates, Wheaton, MD, ⁴Rockefeller University; Hospital for Special Surgery; and New York Genome Center, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Ballerup, Denmark, ⁷Pfizer Inc, New York, NY, ⁸University of Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. This post-hoc analysis investigated the impact of inflammation severity at baseline (BL)…
Abstract Number: 496 • 2017 ACR/ARHP Annual Meeting
Repeated Rituximab Infusions for the Therapy of Rheumatoid Arthritis Is Not Associated with Increased Rates of Serious Infections
Dimitrios A. Pappas^1,2, George W. Reed^1,3, Steve Zlotnick⁴, Jennie Best⁴, Robert Magner³, Gioia Persuitte¹ and Jeffrey D Greenberg^1,5, ¹Corrona, LLC, Southborough, MA, ²Department of Medicine, Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ³University of Massachusetts Medical School, Worcester, MA, ⁴Genentech, Inc., South San Francisco, CA, ⁵NYU School of Medicine, New York, NY
Background/Purpose: Extended observations in clinical trials have not demonstrated an increased risk of serious infection events (SIE) in patients with rheumatoid arthritis (RA) treated with…
Abstract Number: 497 • 2017 ACR/ARHP Annual Meeting
The JAK1 Selective Inhibitor Filgotinib Regulates Both Enthesis and Colon Inflammation in a Mouse Model of Psoriatic Arthritis
Catherine Robin-Jagerschmidt¹, Stéphanie Lavazais¹, Florence Marsais¹, Maté Ongenaert², Alain Monjardet¹, Angélina Cauvin¹, Corinne Saccomani¹, Isabelle Parent¹, Didier Merciris¹, Emilie Chanudet¹, Roland Blanqué¹, Monica Borgonovi¹, Liên Lepescheux¹, Marielle Auberval¹, Sonia Dupont¹, Philippe Clément-Lacroix¹ and René Galien¹, ¹Galapagos SASU, Romainville, France, ²Galapagos NV, Mechelen, Belgium
Background/Purpose: Because of their pleotropic role in cytokine signaling, Janus Kinases (JAKs) are key players in inflammatory diseases. Among the 4 members of the JAK…
Abstract Number: 498 • 2017 ACR/ARHP Annual Meeting
Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
Carlos Fernández-Díaz¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto Guerrero⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez⁹, Bryan Josue Robles Flores¹⁰, Blanca Hernández-Cruz¹¹, Ana Urruticoechea-Arana¹², Olga Maiz¹³, Desiree Palma¹⁴, Luis Arboleya¹⁵, Gema Bonilla¹⁶, Manuel Rodríguez-Gómez¹⁷, Concepción Delgado¹⁸, Rosa Expósito¹⁹, Ana Ruibal Escribano²⁰, Juan Blanco Madrigal²¹, José Antonio Bernal²², Paloma Vela²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Javier Narváez²⁶, Manuel Jose Moreno²⁷, Mireia López-Corbeto²⁸, Natalia Mena-Vazquez²⁹, S. Romero-Yuste³⁰, Clara Aguilera-Cros³¹, Sergi Ordoñez³², Ignacio Villa-Blanco³³, Nuria Vegas-Revenga¹, Victor Mora-Cuesta³⁴, Javier Loricera¹, Miguel Angel González-Gay¹, José Luis Hernandez³⁵ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁵Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de León, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹H. German Trias., Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹²Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹³Hospital Donostia. Spain, San Sebastian, Spain, ¹⁴Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁵Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸H. Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²⁰Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²¹Rheumatology, Hospital de Basurto, BIlbao, Spain, ²²Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ²³Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²⁷Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁸Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²⁹Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³⁰H. Pontevedra, Pontevedra, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Hospital Universitario Arnau de Vilanova, Vilanova, Spain, ³³Hospital de Sierrallana, Sierrallana, Spain, ³⁴Neumology, Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain, ³⁵Division of Internal Medicine., Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain
Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…
Abstract Number: 499 • 2017 ACR/ARHP Annual Meeting
Assessment of Early Improvement in Pain and Other ACR Components As Predictors for Achieving Low Disease Activity or Remission in Three Phase 3 Trials of RA Patients Treated with Baricitinib
Michael Weinblatt¹, Mark C. Genovese², Joel Kremer³, Luna Sun⁴, Himanshu Patel⁴, Alisa Koch⁴, David Muram⁴, Jeffrey R. Curtis⁵, Cynthia J. Larmore⁴ and Baojin Zhu⁴, ¹Brigham and Women’s Hospital, Boston, MA, ²Stanford University Medical Center, Palo Alto, CA, ³The Center for Rheumatology, Albany Medical College, Albany, NY, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The purpose of this analysis was to assess whether early improvement in ACR components could act as predictors of low disease activity (LDA)…
Abstract Number: 500 • 2017 ACR/ARHP Annual Meeting
Low Patient Global Assessment Scores in Rheumatoid Arthritis Are Associated with Pain and Physical Function in Patients Treated with Tofacitinib: A Post-Hoc Analysis of Phase 3 Trials
Vibeke Strand¹, Rieke Alten², Jeffrey Kaine³, Arif Soonasra⁴, Christopher W Murray⁴, Haiyun Fan⁴, Christopher F Mojcik⁵ and Gene Wallenstein⁶, ¹Stanford University, Palo Alto, CA, ²Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ³Sarasota Arthritis Research Center, Sarasota, FL, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined associations of pain and physical function with Patient…
Abstract Number: 501 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
Vibeke Strand¹, Namita Tundia² and Alan Friedman², ¹Stanford University, Palo Alto, CA, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Janus kinase (JAK) inhibitors are being evaluated for treatment of active rheumatoid arthritis (RA). The efficacy of upadacitinib (UPA), a selective JAK inhibitor, in…
Abstract Number: 502 • 2017 ACR/ARHP Annual Meeting
Reduction in Disease Activity in Patients with RA and an Inadequate Response to MTX: Baricitinib Compared to Adalimumab and Placebo
Peter Nash¹, Janet E. Pope², Anabela Cardoso³, Marta Casillas³, Douglas E. Schlichting³, Baojin Zhu³, Scott D. Beattie³ and Josef S. Smolen⁴, ¹University of Queensland, Brisbane, Australia, ²St. Joseph's Health Care, London, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib (BARI), is an oral Janus kinase (JAK)1/JAK2 selective inhibitor for treatment of patients with moderately to severely active RA. RA-BEAM was a phase…
Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…
Abstract Number: 504 • 2017 ACR/ARHP Annual Meeting
Monotherapy with Filgotinib, a JAK1-Selective Inhibitor, Reduces Disease-Related Biomarkers in Rheumatoid Arthritis Patients
Peter C. Taylor¹, René Galien², Annegret Van der Aa³, Corinne Jamoul³, Pille Harrison³, Chantal Tasset³, Yang Pan⁴, Lovely Goyal⁴, Wanying Li⁴ and Jacqueline Tarrant⁴, ¹Kennedy Institute of Rheumatology, London, United Kingdom, ²Galapagos SASU, Romainville, France, ³Galapagos NV, Mechelen, Belgium, ⁴Gilead Sciences, Foster City, CA
Background/Purpose: The JAK1 selective inhibitor filgotinib (GLPG0634, GS-6034) has been evaluated in a 24-week phase 2B study (DARWIN 2) as monotherapy in active rheumatoid arthritis…
Abstract Number: 505 • 2017 ACR/ARHP Annual Meeting
Exposure-Response Analyses of the Effect of Upadacitinib on ACR Responses in the Phase 2b Rheumatoid Arthritis Trials in Patients with Inadequate Response to Methotrexate or to Anti-Tumor Necrosis Factor Therapy
Ben Klünder¹, Mohamed-Eslam F. Mohamed², Heidi S. Camp² and Ahmed A. Othman², ¹AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ²AbbVie, North Chicago, IL
Background/Purpose: Upadacitinib, a selective JAK1 inhibitor, demonstrated favorable efficacy in two Phase 2 studies in subjects with moderate to severe rheumatoid arthritis (RA) who had…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].